undamentalytics Newsletter
Sign in

Karyopharm Therapeutics Inc. (KPTI) stock

Add to watchlist

Add holding +

NASDAQ: KPTI Nasdaq Biotechnology Next results ~November 3, 2026

C+ Fundamentals grade

Karyopharm Therapeutics Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Karyopharm Therapeutics Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Karyopharm Therapeutics Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 7 selling0 purchases and 21 sales by directors and officers, last 12 monthsInsider trades
  • Funds64 adding, 28 cuttingOf 23 active managers that changed their stake, 12 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Karyopharm Therapeutics files

Where Karyopharm Therapeutics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $147m, up 6.8% on a year earlier, about the same pace as a quarter earlier. Free-cash-flow margin rose to -44.6% from -75.0% a year earlier. Operating margin widened to -56.2% from -83.9%. It passes 0 of our 3 financial-health checks.

Our model value for Karyopharm Therapeutics is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 13, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Karyopharm Therapeutics Inc.'s trailing-twelve-month revenue grew 6.8% year on year, with a free-cash-flow margin of -44.6%.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 36.5% while net income fell 81.9%: a 118pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 27.8 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Loss-making. Operating margin is -56.2%: costs exceed revenue.
  • Burning cash. Free cash flow was -44.6% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 22.0% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 171% and a beta of 1.0 against the S&P 500.
  • Heavily shorted. 32.2% of the shares available to trade are sold short (5.2 days of average volume to cover).
  • Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.

Latest results: FY2026 Q2

Filed August 13, 2026
Earnings per share
-$2.32 against an average estimate of -$1.39: missed by 66.9%
Revenue
$33m, down 11.9% on a year earlier
Share reaction
-0.5% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500
Guidance given
total revenue $130m to $150m (full year 2026); U.S. XPOVIO net product revenue $115m to $130m (full year 2026)
Next report
November 3, 2026; average EPS estimate -$1.31

Karyopharm Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-83.1%
  • 1 week-76.8%
  • 1 month-86.0%
  • This year-98.5%
  • 1 year-98.1%
  • 5 years-99.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$147M
Operating margin
-56.2%
Net margin
-153.3%
EPS (TTM, diluted)
$-52.58

Growth

Revenue growth
+6.8%
Change in growth rate
+0.5 pts

Cash

Free cash flow (TTM)
-$65.3M
FCF margin
-44.6%
Stock pay % of revenue
7.9%

Earnings

Last results
August 13, 2026

News & updates

Updated November 3, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Our research
  2. Announcement
  3. Announcement
  4. Announcement
  5. Governance
  6. Agreement
  7. Announcement
  8. Results
  9. Guidance
  10. Announcement
  11. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Karyopharm Therapeutics Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Karyopharm Therapeutics Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.3%: the 10-year Treasury yield (4.9%) plus a beta of 1.19 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$19 ~$18–$61 Left out: out of range vs price (173.84x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Karyopharm Therapeutics Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025
Share price$198.75$141.00$144.00$140.55$287.55$232.20$96.45$51.00$12.97$10.14$7.36
Market value$16m$12m$15m$17754$40m$37m$16m$9.3bn$98818$85734$80m
+ Net debt (− = net cash)−$58m−$50m−$69m−$15m−$19m$32m$3m$35m$119m$32m$34m
Enterprise value−$43m−$38m−$54m−$15m$21m$69m$19m$9.3bn$119m$32m$115m
Multiples
Price / sales 63.0x76.4x9.2x0.0x1.0x0.3x0.1x59.1x0.0x0.0x0.6x
Price / earnings ———————————
Price / free cash flow ———————————
EV / EBITDA ———————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

8 /100

Weak moat

How hard Karyopharm Therapeutics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -57.7% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -135.7%; its worst year was -68034.9%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 9 years, at a median -89.6% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 5411.5% over five years; stock-based pay has been a median 19.7% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026. Analysts expect revenue of $34m and EPS of −$1.31 (range −$1.37 to −$1.26) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$5.84 +52% $136m −7%
Next −$2.82 +52% $174m +28%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +18.0% on 90 days ago. In the last 30 days, 1 analyst raised Karyopharm Therapeutics Inc.'s forecast and 1 cut it.

Consensus EPS forecast Karyopharm Therapeutics Inc., last 90 days
−$6.00 −$4.00 −$2.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$4.95 Current fiscal year, 60 days ago: −$4.95 Current fiscal year, 30 days ago: −$4.95 Current fiscal year, 7 days ago: −$4.76 Current fiscal year, Now: −$5.84 −$5.84 Next fiscal year, 90 days ago: −$4.89 Next fiscal year, 60 days ago: −$4.89 Next fiscal year, 30 days ago: −$4.89 Next fiscal year, 7 days ago: −$3.21 Next fiscal year, Now: −$2.82 −$2.82

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$4.95−$4.89
60 days ago −$4.95−$4.89
30 days ago −$4.95−$4.89
7 days ago −$4.76−$3.21
Now −$5.84−$2.82

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$1.39 −$2.32 −66.9%
Mar 2026 −$1.44 −$1.24 +14.1%
Dec 2025 −$2.00 −$2.23 −11.4%
Sept 2025 −$3.25 −$3.82 −17.5%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 13, 2026
  • Total revenue full year 2026 $130m to $150m Maintained
    “Total revenue to be in the range of $130 million to $150 million.” source
  • U.S. XPOVIO net product revenue · XPOVIO U.S. full year 2026 $115m to $130m Maintained
    “U.S. XPOVIO net product revenue to be in the range of $115 million to $130 million.” source
  • R&D and SG&A expenses full year 2026 $230m to $245m Non-GAAP
    “R&D and selling, general and administrative (SG&A) expenses to be in the range of $230 million to $245 million, excluding certain one-time costs that the Company may incur associated with its endometrial cancer program and evaluating financing opportunities and/or strategic transactions.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

5 analysts, Oct 2026
Buy480%
Hold120%
Sell00%

Monthly trend

  1. Oct 20262215
  2. Sep 20262215
  3. Aug 20262226

Counts of recommendations published by analysts covering Karyopharm Therapeutics Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
32.2%
of tradable shares
Days to cover
5.19
at average volume
Short interest, 1 month
−8%
to October 15, 2026
Held by institutions
96%
of shares
Held by insiders
4.7%
of shares
Employees
228
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
KPTI−59%−47%−75%−22%−27%−99%
Industry peers (median)−35%−57%−17%−29%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
KPTI25%50%33%42%33%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
KPTI−75%−83%−85%−64%−72%−99%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 100% from March 2, 2020 to November 2, 2026. Getting back needed a 371150% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.11 – $10.67
From 52-week high
−99.0%
vs 50-day average
−90.5%
vs 200-day average
−98.1%
Volatility (1 year)
171%
Beta vs S&P 500
1.01

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±7.5%
After a week
4 up, 8 down
typical move ±13.7%
After a month
3 up, 9 down
typical move ±19.8%
Results releasedNext dayS&P 500 next day5 days21 days
August 13, 2026 −0.5% +0.5% −10.3% −21.2%
May 14, 2026 −13.3% −0.4% −8.9% +8.9%
February 12, 2026 +16.4% −1.5% +31.2% +16.0%
January 12, 2026 −8.9% 0.0% −31.5% −15.1%
November 3, 2025 −2.6% −1.0% −6.2% −5.9%
October 8, 2025 +0.9% +0.3% +3.1% −9.5%
August 11, 2025 +2.0% +0.9% +41.9% +57.6%
May 12, 2025 −18.1% +4.0% −14.7% −27.0%
February 19, 2025 −3.2% −0.2% +4.0% −35.0%
January 13, 2025 −12.0% +0.3% −4.5% −18.5%
November 5, 2024 −4.9% +3.7% −3.8% −14.7%
August 6, 2024 −6.9% +0.2% −4.5% −8.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Karyopharm Therapeutics Inc.
$135M $140M $145M $150M $155M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $145.9M Revenue (TTM), FY23 Q4: $146M Revenue (TTM), FY24 Q1: $140.5M Revenue (TTM), FY24 Q2: $145.7M Revenue (TTM), FY24 Q3: $148.4M Revenue (TTM), FY24 Q4: $145.2M Revenue (TTM), FY25 Q1: $142.1M Revenue (TTM), FY25 Q2: $137.3M Revenue (TTM), FY25 Q3: $142.5M Revenue (TTM), FY25 Q4: $146.1M Revenue (TTM), FY26 Q1: $151.1M Revenue (TTM), FY26 Q2: $146.6M $146.6M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $145.9M
FY23 Q4 $146M
FY24 Q1 $140.5M
FY24 Q2 $145.7M
FY24 Q3 $148.4M
FY24 Q4 $145.2M
FY25 Q1 $142.1M
FY25 Q2 $137.3M
FY25 Q3 $142.5M
FY25 Q4 $146.1M
FY26 Q1 $151.1M
FY26 Q2 $146.6M
Revenue growth, TTM YoY Karyopharm Therapeutics Inc.
-60% -40% -20% 0% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -41.6% Revenue growth, TTM YoY, FY23 Q4: -7.0% Revenue growth, TTM YoY, FY24 Q1: -5.2% Revenue growth, TTM YoY, FY24 Q2: -0.2% Revenue growth, TTM YoY, FY24 Q3: 1.8% Revenue growth, TTM YoY, FY24 Q4: -0.5% Revenue growth, TTM YoY, FY25 Q1: 1.2% Revenue growth, TTM YoY, FY25 Q2: -5.8% Revenue growth, TTM YoY, FY25 Q3: -4.0% Revenue growth, TTM YoY, FY25 Q4: 0.6% Revenue growth, TTM YoY, FY26 Q1: 6.3% Revenue growth, TTM YoY, FY26 Q2: 6.8% 6.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -41.6%
FY23 Q4 -7.0%
FY24 Q1 -5.2%
FY24 Q2 -0.2%
FY24 Q3 1.8%
FY24 Q4 -0.5%
FY25 Q1 1.2%
FY25 Q2 -5.8%
FY25 Q3 -4.0%
FY25 Q4 0.6%
FY26 Q1 6.3%
FY26 Q2 6.8%
Operating margin (TTM) Karyopharm Therapeutics Inc.
-100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -86.1% Operating margin (TTM), FY23 Q4: -88.7% Operating margin (TTM), FY24 Q1: -94.3% Operating margin (TTM), FY24 Q2: -89.9% Operating margin (TTM), FY24 Q3: -84.9% Operating margin (TTM), FY24 Q4: -82.2% Operating margin (TTM), FY25 Q1: -83.7% Operating margin (TTM), FY25 Q2: -83.9% Operating margin (TTM), FY25 Q3: -73.1% Operating margin (TTM), FY25 Q4: -62.1% Operating margin (TTM), FY26 Q1: -55.7% Operating margin (TTM), FY26 Q2: -56.2% -56.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -86.1%
FY23 Q4 -88.7%
FY24 Q1 -94.3%
FY24 Q2 -89.9%
FY24 Q3 -84.9%
FY24 Q4 -82.2%
FY25 Q1 -83.7%
FY25 Q2 -83.9%
FY25 Q3 -73.1%
FY25 Q4 -62.1%
FY26 Q1 -55.7%
FY26 Q2 -56.2%
FCF margin (TTM) Karyopharm Therapeutics Inc.
-100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -69.2% FCF margin (TTM), FY23 Q4: -63.5% FCF margin (TTM), FY24 Q1: -83.8% FCF margin (TTM), FY24 Q2: -89.6% FCF margin (TTM), FY24 Q3: -81.1% FCF margin (TTM), FY24 Q4: -87.9% FCF margin (TTM), FY25 Q1: -86.3% FCF margin (TTM), FY25 Q2: -75.0% FCF margin (TTM), FY25 Q3: -62.7% FCF margin (TTM), FY25 Q4: -51.6% FCF margin (TTM), FY26 Q1: -39.1% FCF margin (TTM), FY26 Q2: -44.6% -44.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -69.2%
FY23 Q4 -63.5%
FY24 Q1 -83.8%
FY24 Q2 -89.6%
FY24 Q3 -81.1%
FY24 Q4 -87.9%
FY25 Q1 -86.3%
FY25 Q2 -75.0%
FY25 Q3 -62.7%
FY25 Q4 -51.6%
FY26 Q1 -39.1%
FY26 Q2 -44.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 1 0 0 0 0 2 30 41 108 210 157 146 145 146 147
EBITDA −10 −16 −34 −76 −118 −110 −130 −179 −188 −171 −97 −142 −129 −119 −90 −82
Operating income −10 −16 −34 −76 −119 −111 −131 −180 −189 −172 −98 −142 −130 −119 −91 −82
Net income −10 −16 −34 −76 −118 −110 −129 −178 −200 −196 −124 −165 −143 −76 −196 −225
Diluted EPS −$923.26 −$804.59 −$502.53 −$72.82 −$99.49 −$87.50 −$84.21 −$1411.41 −$1447.37 −$1222.62 −$49.44 −$907.98 −$18.79 −$14.00 −$17.93 —
Growth (year on year)
Revenue — +317.1% −39.0% −40.8% +9.2% −38.4% +942.2% +>999% +34.8% +164.3% +94.1% −25.1% −7.0% −0.5% +0.6% +6.8%
Margins
EBITDA margin <−999% <−999% <−999% <−999% <−999% <−999% <−999% −590.5% −460.5% −158.1% −46.5% −90.1% −88.3% −82.0% −61.9% −56.1%
Operating margin <−999% <−999% <−999% <−999% <−999% <−999% <−999% −593.0% −462.9% −159.0% −46.8% −90.5% −88.7% −82.2% −62.1% −56.2%
Net margin <−999% <−999% <−999% <−999% <−999% <−999% <−999% −588.1% −488.1% −181.6% −59.1% −105.2% −98.0% −52.6% −134.2% −153.3%
Free-cash-flow margin <−999% <−999% <−999% <−999% <−999% <−999% <−999% −532.3% −467.1% −148.4% −51.2% −95.3% −63.5% −87.9% −51.6% −44.6%
Cash flow
Cash from operations −9 −16 −30 −51 −94 −84 −74 −159 −191 −160 −107 −150 −93 −127 −75 −65
Capital spending 0 0 0 3 1 0 0 2 0 0 0 0 0 0 0 0
Free cash flow −9 −16 −30 −54 −95 −84 −74 −161 −191 −160 −107 −150 −93 −128 −75 −65
Stock-based pay 0 1 4 14 17 22 20 17 15 24 30 35 22 18 14 12
Free cash flow after stock pay −9 −16 −34 −69 −113 −107 −94 −179 −206 −185 −137 −185 −114 −146 −89 −77
Balance sheet
Cash 7 0 156 151 58 50 69 118 129 86 190 135 52 62 61 55
Total debt 0 0 0 0 0 0 0 103 110 118 193 170 171 95 95 85
Net debt (negative = net cash) −7 −0 −156 −151 −58 −50 −69 −15 −19 32 3 35 119 32 34 30
Diluted shares — — — — — — — — — — — 182m — — 11m —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

0 of 3 checks passed · June 30, 2026
What it owns · $111m
Short-term assets $106mLonger-term assets $5m
What it owes, and who funded it · $441m
Short-term liabilities $134mLonger-term liabilities $307mShareholders' equity $-330m
  • Short-term assets cover short-term liabilities $106m of assets due within a year against $134m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $106m short-term assets against $307m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$82m against $49m of interest.

From Karyopharm Therapeutics Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
82.5%
of revenue
Sales & admin spending
69.6%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated KPTI BEAM AGEN IBRX NUVB MESO Median
Revenue, last 12 months $147m $156m $133m $166m $170m $120m $56m
Revenue growth, last 12 months 6.8% 158.9% 30.5% 192.9% >999% 599.2% 12.6%
Revenue growth, 3-year average 0.1% 24.9% 10.1% 554.3% — — 13.7%
Revenue growth, latest quarter −11.9% −94.2% 34.4% 93.9% 555.6% — 10.2%
Gross margin — — 99.5% 99.3% 54.3% 86.1% 82.9%
Operating margin −56.2% −242.3% 27.3% −151.9% −81.0% — −189.4%
Operating margin, 3-year average −76.7% −344.8% −43.3% <−999% <−999% — −363.5%
Net margin −153.3% −54.7% 69.2% −598.6% −88.2% −47.8% −169.8%
Cash from operations / revenue −44.6% −230.3% −74.2% −169.6% −70.9% −36.4% −168.0%
Free-cash-flow margin −44.6% −238.9% −74.2% −173.8% −72.2% −37.1% −162.4%
Free-cash-flow margin, 3-year average −69.7% −290.8% −105.5% <−999% <−999% — −310.0%
Stock pay / revenue 7.9% 52.2% 8.0% 20.7% 20.9% 12.4% 20.0%
Change in share count 22.0% 16.3% 50.4% 26.1% 9.5% 7.2% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 6.8% 12.6% 101 of 172
Change in growth rate Growth +0.5pp -0.1pp 78 of 172
Operating margin Profitability -56.2% -189.4% 65 of 175
Net margin Profitability -153.3% -157.3% 88 of 180
Free-cash-flow margin Cash generation -44.6% -145.4% 65 of 176
Stock pay as % of revenue Cash generation 7.9% 19.2% 50 of 179

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $115M 78.6% ▲ 1.8%
License and Other $31.2M 21.4% ▼ 3.8%

From Karyopharm Therapeutics Inc.'s 10-K filed February 13, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$213M
Institutions reporting
96
Shares held vs prior quarter
▲ 20.8%
Positions opened / closed
34 / 14

Top buyers and sellers, Q2 2026: 64 institutions bought and 28 sold ; the biggest buyer was Kalehua Capital Management LLC (+1.4M shares) and the biggest seller Commodore Capital LP (−1.9M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
RA Capital Management, L.P. $18.7M 1.9M 8.8% 0.0%
Adage Capital Partners Gp, L.L.C. $14.9M 1.5M 7.0% ▼ 15.8%
Acorn Capital Advisors, LLC $14.8M 1.5M 7.0% ▲ 427.4%
Goldman Sachs Group Inc $13.9M 1.4M 6.5% ▲ 50.3%
Blackrock, Inc. $13.9M 1.4M 6.5% ▲ 479.3%
Kalehua Capital Management LLC $13.4M 1.4M 6.3% New
Vanguard Capital Management LLC $9.4M 959K 4.4% ▲ 29.6%
Catalio Capital Management, LP $9.2M 941K 4.3% ▲ 4.8%
Avidity Partners Management LP $9M 924K 4.2% ▼ 0.3%
T. Rowe Price Investment Management, Inc. $7.7M 786K 3.6% ▼ 49.0%
Two Sigma Investments, LP $6.8M 695K 3.2% ▲ 359.7%
Nea Management Company, LLC $5.6M 577K 2.6% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Karyopharm Therapeutics Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $351,422 21 trades by 7 insiders · 0% under pre-set plans
Net ▼ $351,422 net selling
Insider Date Trade Shares Price Value
Abate Kristin Chief Accounting Officer October 16, 2026 Sell 4,788 $0.34 $1,647
Abate Kristin Chief Accounting Officer October 1, 2026 Sell 378 $1.19 $450
Abate Kristin Chief Accounting Officer September 1, 2026 Sell 19 $2.02 $38
Poulton Stuart EVP, Chief Development Officer July 28, 2026 Sell 189 $7.10 $1,342
Mano Michael EVP, CLO&Secretary May 14, 2026 Sell 266 $9.50 $2,527
Paulson Richard A. President and CEO May 14, 2026 Sell 2,203 $9.50 $20,928
Abate Kristin Chief Accounting Officer May 14, 2026 Sell 53 $9.50 $504
Cheng Sohanya Roshan EVP & Chief Commercial Officer May 14, 2026 Sell 324 $9.50 $3,078
Rangwala Reshma EVP & Chief Medical Officer May 14, 2026 Sell 408 $9.50 $3,876
Poulton Stuart EVP, Chief Development Officer May 14, 2026 Sell 403 $9.50 $3,828
Rangwala Reshma EVP & Chief Medical Officer April 21, 2026 Sell 449 $8.94 $4,014
Poulton Stuart EVP, Chief Development Officer March 2, 2026 Sell 5,101 $9.41 $48,000

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 28, 2026 estimated from the company's past filing pattern, not announced

  • August 13, 2026
  • May 14, 2026
  • February 12, 2026
  • January 12, 2026
  • November 3, 2025
  • October 8, 2025

Recent SEC filings

Data status

When each part of this page on Karyopharm Therapeutics Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Karyopharm Therapeutics Inc. in brief

What does Karyopharm Therapeutics Inc. do?
Karyopharm Therapeutics Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Karyopharm Therapeutics Inc.'s stock ticker?
Karyopharm Therapeutics Inc. trades under the ticker KPTI on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Karyopharm Therapeutics Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Karyopharm Therapeutics Inc. reported revenue of $147M, 6.8% higher than a year earlier, according to its SEC filings.
What is Karyopharm Therapeutics Inc.'s free cash flow?
Karyopharm Therapeutics Inc.'s free-cash-flow margin is -44.6% of revenue over the trailing twelve months, ranking 65 of the 176 biotechnology companies we cover.
Who are Karyopharm Therapeutics Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are RA Capital Management, L.P., Adage Capital Partners Gp, L.L.C. and Acorn Capital Advisors, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Karyopharm Therapeutics Inc.'s market cap?
On December 31, 2025, Karyopharm Therapeutics Inc.'s market capitalisation was about $80.5M and net debt of $34.3M. Market figures come from third-party market data and may be delayed.
Who are Karyopharm Therapeutics Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Karyopharm Therapeutics Inc. are Beam Therapeutics Inc., Agenus Inc, Immunitybio, Inc., Nuvation Bio Inc. and Mesoblast LTD. The side-by-side comparison below sets their revenue, margins and growth against Karyopharm Therapeutics Inc.'s.
Are insiders buying or selling Karyopharm Therapeutics Inc. stock?
Over the last 12 months, Karyopharm Therapeutics Inc.'s directors and officers reported 0 open-market purchases and 21 sales on Form 4. The insider trading page charts every trade.
When is Karyopharm Therapeutics Inc.'s next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Karyopharm Therapeutics Inc. announces its own schedule.